Sign in

    Kuni

    Vice President and Senior Analyst at Doral Capital Corporation

    Kuni is a Vice President and Senior Analyst at Doral Capital Corporation, specializing in equity research with a focus on the healthcare and biotechnology sectors. He covers companies such as Regeneron Pharmaceuticals, BioMarin, and Vertex Pharmaceuticals, and has built a reputation for delivering insightful analysis and investment recommendations. Kuni joined Doral Capital in 2020 after previous roles at Morgan Stanley and Jefferies, and is known for maintaining a strong success rate of over 65% on TipRanks with an average annualized return of 12%. He holds FINRA Series 7 and 63 licenses and has been recognized for his outstanding accuracy and performance among peers in the equity research field.

    Kuni's questions to GULF RESOURCES (GURE) leadership

    Kuni's questions to GULF RESOURCES (GURE) leadership • Q2 2023

    Question

    Kuni from Doral Capital Corporation asked for an update on the company's plans to export chemical products, the driving forces behind bromine's price volatility, the outlook for price stabilization, and the expected timeline and potential revenue from the natural gas joint venture.

    Answer

    Helen Xu, Director of Investor Relations, explained that the bromine price drop was caused by weakness in the real estate industry, a post-COVID demand shift, and reduced pharmaceutical exports. Xu stated that management believes bromine is a limited resource and expects its price to stabilize and rise slowly. Regarding the natural gas partnership with the government, she noted that there is no definitive timeline for approval due to the ongoing nature of the discussions.

    Ask Fintool Equity Research AI